Ovid Therapeutics Inc.
Ovid Therapeutics Inc. (NASDAQ: OVID) is a biopharmaceutical company dedicated to developing small molecule medicines for brain disorders characterized by neuronal hyperexcitation. The company focuses on creating therapeutics for epilepsy, psychosis, schizophrenia, and related neurological and psychiatric conditions… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Ovid Therapeutics Inc. does
In the company’s own words
Ovid Therapeutics Inc. (NASDAQ: OVID) is a biopharmaceutical company dedicated to developing small molecule medicines for brain disorders characterized by neuronal hyperexcitation. The company focuses on creating therapeutics for epilepsy, psychosis, schizophrenia, and related neurological and psychiatric conditions with significant unmet medical need. Ovid's website is www.ovidtherapeutics.com.
The company operates a pipeline of clinical-stage drug development programs built through strategic in-licensing agreements and internal research and development efforts. Ovid's lead program, OV329, is a next-generation GABA-aminotransferase inhibitor designed to treat drug-resistant focal onset seizures and developmental and epileptic encephalopathies including tuberous sclerosis complex seizures and infantile spasms. The company also maintains a portfolio of potassium-chloride cotransporter 2 (KCC2) direct activators, with OV4071 as the most advanced oral program intended for psychosis associated with Parkinson's disease and Lewy body dementia, as well as potential applications in schizophrenia and other psychiatric conditions.
Ovid employs 23 professionals with deep expertise in neurology, psychiatry, and drug development, including physicians and scientists with advanced degrees. The company's management team collectively brings experience in the successful development and commercial launch of more than 25 medicines, many targeting the central nervous system.
The company's business model centers on acquiring or in-licensing promising drug candidates and advancing them through clinical development. Ovid has established key licensing agreements, including an exclusive worldwide license to a KCC2 transporter portfolio from AstraZeneca and exclusive rights to OV329 from Northwestern University. The company also maintains a royalty-bearing agreement with Marinus Pharmaceuticals related to ganaxolone commercialization and holds an equity investment in Gensaic, Inc. for collaborative genetic medicine development.
Ovid currently outsources all manufacturing to contract manufacturers and has not yet established commercial infrastructure, though the company maintains internal market access and commercial capabilities to inform pipeline strategy. The company operates as a smaller reporting company and is not a shell company.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1636651
- SIC
- 2834
Financial performance, year by year
Fiscal 2017–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Ovid Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Ovid Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Ovid Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Ovid Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Ovid Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”